title: Levels of evidence needed for changing indications, contraindications, and Food and Drug Administration labeling: the case of metformin.
authors.forename: Dean T
authors.initials: DT
authors.lastname: Eurich
authors.forename: Sumit R
authors.initials: SR
authors.lastname: Majumdar
authors.forename: Finlay A
authors.initials: FA
authors.lastname: McAlister
authors.forename: Ross T
authors.initials: RT
authors.lastname: Tsuyuki
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Johnson
mesh_terms: D002170:Canada / Q000453:epidemiology; D002561:Cerebrovascular Disorders / Q000401:mortality; D000075202:Contraindications; D003324:Coronary Artery Disease / Q000401:mortality; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000453:epidemiology; D004348:Drug Labeling; D006333:Heart Failure / Q000150:complications*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D058729:Peripheral Arterial Disease / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention; D014481:United States / Q000453:epidemiology
chemical_list: D007004:Hypoglycemic Agents; D008687:Metformin